KEYTRUDA is Merck's anti-PD-1 therapy for metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy
We regularly give our reviewer community the chance to win big prizes, here are some of our latest winners
DCN Dx specializes in lateral flow diagnostics development and manufacturing, and IVD regulatory consulting and clinical research.
The technology helping to save young lives by enabling quick testing of patient samples
Dr. Luca Quagliata explains how molecular profiling could transform the way we treat cancer, and how his work is enabling the global adoption of this technology – in the face of clinical challenges and diversity
The new genetic analyzer supports both clinical as well as research for Sanger sequencing and fragment analysis in targeted genomic testing
Researchers at MedAustron Ion Therapy Center and Karl Landsteiner University of Health Sciences improve methods for energy deposition into tumour tissue
First dose delivered to patients in a multi-center U.S. clinical trial to evaluate novel gamma-delta T cell cancer therapy
Cielo Dx qPCR systems for in vitro diagnostic (IVD) use brings the accuracy and sensitivity that clinical laboratories demand.
Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers
